Paul Kalra

Oct 25, 2024 | onlinelibrary.wiley.com | Paul Foley |Paul Kalra |John Cleland |Mark C. Petrie

Introduction Iron deficiency is common in patients with heart failure and clinical trials suggest that correction with high-dose intravenous (IV) iron improves symptoms and quality of life and reduces the risk of heart failure hospitalization.1-3 There is a theoretical risk that iron supplements might increase the risk or severity of infection.

Mar 28, 2024 | onlinelibrary.wiley.com | Kieran F. Docherty |John McMurray |Paul Kalra |John G.F. Cleland

Introduction Iron deficiency is common in patients with heart failure and is associated with anaemia and a poorer prognosis.

Jun 6, 2023 | cfrjournal.com | Harriette Van Spall |James L. Januzzi |Paul Kalra

ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US)  to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients.

May 25, 2023 | cfrjournal.com | Paul Kalra |John GF Cleland |Stephen Greene

"Hello. My name is Paul Kalra. I’m consultant cardiologist and heart failure specialist at Portsmouth Hospital's University NH Trust in the United Kingdom. And I was chief investigator for IRONMAN, which was atrial that was funded by the British Heart Foundation. Please briefly outline the IRONMAN Trial. So, IRONMAN was a randomized trial of intravenous ferric derisomaltose and usual care versus usual care alone in patients with heart failure, a reduced ejection fraction and an iron deficiency.

May 24, 2023 | cfrjournal.com | Paul Kalra |John GF Cleland |Stephen Greene

ESC-HFA 23 - Prof John Cleland (University of Glasgow, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562). IRONMAN was a randomised, open-label multicenter trial, which aimed to assess the effectiveness of intravenous iron in patients with heart failure and iron deficiency as compared to standard care. It demonstrated that the administration of IV FDI was associated with lower rates of recurrent heart failure hospitalisations and cardiovascular death.